NEXT Financial Group Inc reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 42.4% during the first quarter, Holdings Channel reports. The institutional investor owned 3,659 shares of the life sciences company’s stock after selling 2,691 shares during the period. NEXT Financial Group Inc’s holdings in Illumina were worth $676,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC increased its stake in Illumina by 19.5% in the first quarter. Parametric Portfolio Associates LLC now owns 178,939 shares of the life sciences company’s stock valued at $30,534,000 after buying an additional 29,164 shares in the last quarter. Exane Asset Management acquired a new stake in Illumina during the first quarter valued at approximately $1,450,000. Toronto Dominion Bank increased its stake in Illumina by 55.9% in the first quarter. Toronto Dominion Bank now owns 39,486 shares of the life sciences company’s stock valued at $6,736,000 after buying an additional 14,158 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in Illumina by 3.4% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 3,083 shares of the life sciences company’s stock valued at $516,000 after buying an additional 100 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Illumina by 28.9% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,852 shares of the life sciences company’s stock valued at $1,852,000 after buying an additional 2,431 shares in the last quarter. Hedge funds and other institutional investors own 92.79% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded up 0.64% on Friday, hitting $177.01. 1,061,794 shares of the stock traded hands. The stock has a 50 day moving average of $178.41 and a 200-day moving average of $156.53. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $189.48. The stock has a market cap of $25.84 billion, a PE ratio of 35.82 and a beta of 0.79.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.64. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The company had revenue of $598 million during the quarter, compared to the consensus estimate of $590.51 million. During the same quarter in the prior year, the firm posted $0.71 earnings per share. The firm’s revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts expect that Illumina, Inc. will post $3.63 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was first published by Mideast Time and is owned by of Mideast Time. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.mideasttime.com/illumina-inc-ilmn-shares-sold-by-next-financial-group-inc/1708046.html.
Several analysts recently issued reports on the stock. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 price objective for the company in a report on Monday, April 24th. Leerink Swann upped their price objective on shares of Illumina from $134.00 to $138.00 and gave the stock a “market perform” rating in a report on Thursday, February 9th. Cantor Fitzgerald upped their price objective on shares of Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a report on Wednesday, April 26th. Morgan Stanley reaffirmed an “underweight” rating and set a $115.00 price objective (up from $108.00) on shares of Illumina in a report on Monday. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $150.00 price objective on shares of Illumina in a report on Tuesday, February 21st. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $164.97.
In related news, Director A Blaine Bowman sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 12th. The stock was sold at an average price of $172.72, for a total value of $518,160.00. Following the sale, the director now directly owns 18,704 shares in the company, valued at $3,230,554.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction that occurred on Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total value of $300,995.63. Following the completion of the sale, the senior vice president now owns 10,936 shares in the company, valued at $2,045,797.52. The disclosure for this sale can be found here. Insiders sold 35,521 shares of company stock valued at $6,465,772 in the last ninety days. 1.60% of the stock is currently owned by insiders.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.